The prognostic utility of the "Tumor Burden Score" based on preoperative radiographic features of colorectal liver metastases

被引:55
作者
Sasaki, Kazunari [1 ]
Margonis, Georgios A. [1 ]
Andreatos, Nikolaos [1 ]
Zhang, Xu-Feng [1 ,2 ]
Buettner, Stefan [1 ]
Wang, Jaeyun [1 ]
Deshwar, Amar [1 ]
He, Jin [1 ]
Wolfgang, Christopher L. [1 ]
Weiss, Matthew [1 ]
Pawlik, Timothy M. [1 ,2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA
[2] Ohio State Univ, Dept Surg, Wexner Med Ctr, Columbus, OH 43210 USA
关键词
imaging; prognosis; TBS; HEPATIC RESECTION; RESPONSE EVALUATION; CANCER; RECURRENCE; CHEMOTHERAPY; CARCINOMA; PATTERNS; MUTATION; SURGERY;
D O I
10.1002/jso.24678
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundRecently, a tumor-burden metro ticket score (TBS) based on final pathology was proposed to predict outcome following resection of colorectal liver metastasis (CRLM). We sought to validate the TBS prognostic tool using preoperative radiologic cross-sectional imaging. MethodsImaging TBS was defined on a Cartesian plane that incorporated both maximum tumor size (x-axis) and lesion number (y-axis) assessed by pre-operative imaging. The discriminatory power (area under the curve [AUC]) and goodness-of-fit (Harrel's C statistic and Somer's D statistics) of the imaging TBS model was assessed. ResultsImaging and pathologic TBS correlated strongly (r=0.76, P<0.01). Among patients treated with neoadjuvant therapy, the correlation was strongest among patients with progressive disease/stable disease (PD/SD) (r=0.81). Discriminatory power of the imaging-based versus pathology-based TBS models were comparable (AUC 0.64 vs. 0.67, respectively P>0.05). An incremental worsening of long-term survival was noted as the imaging TBS increased (5-year OS: Zone1, Zone2, and Zone361.3%, 46.7%, and 38.5%, respectively; P=0.03). The imaging-based TBS model outperformed the classic pathology-based Fong score (Harrel's C-index: imaging TBS-0.56 vs. Fong score-0.53; Somers'D-index: imaging TBS-012 vs. Fong score-0.06). ConclusionsImaging-based TBS was superior to traditional tumor size and number and was comparable to pathology-based TBS. Imaging-based TBS may have the potential to facilitate improved preoperative risk stratification of patients with CRLM.
引用
收藏
页码:515 / 523
页数:9
相关论文
共 32 条
  • [1] The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus
    Adam, Rene
    De Gramont, Aimery
    Figueras, Joan
    Guthrie, Ashley
    Kokudo, Norihiro
    Kunstlinger, Francis
    Loyer, Evelyne
    Poston, Graeme
    Rougier, Philippe
    Rubbia-Brandt, Laura
    Sobrero, Alberto
    Tabernero, Josep
    Teh, Catherine
    Van Cutsem, Eric
    [J]. ONCOLOGIST, 2012, 17 (10) : 1225 - 1239
  • [2] Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?
    Adam, Rene
    Wicherts, Dennis A.
    de Haas, Robbert J.
    Ciacio, Oriana
    Levi, Francis
    Paule, Bernard
    Ducreux, Michel
    Azoulay, Daniel
    Bismuth, Henri
    Castaing, Denis
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) : 1829 - 1835
  • [3] ADSON MA, 1984, ARCH SURG-CHICAGO, V119, P647
  • [4] [Anonymous], ANN SURG
  • [5] Is the Clinical Risk Score for Patients with Colorectal Liver Metastases Still Useable in the Era of Effective Neoadjuvant Chemotherapy?
    Ayez, Ninos
    Lalmahomed, Zarina S.
    van der Pool, Anne E. M.
    Vergouwe, Yvonne
    van Montfort, Kees
    de Jonge, Jeroen
    Eggermont, Alexander M. M.
    IJzermans, Jan N. M.
    Verhoef, Cornelis
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (10) : 2757 - 2763
  • [6] Response Evaluation in Patients With Colorectal Liver Metastases: RECIST Version 1.1 Versus Modified CT Criteria
    Chung, Woo-Suk
    Park, Mi-Suk
    Shin, Sang Joon
    Baek, Song-Ee
    Kim, Yeo-Eun
    Choi, Jin Young
    Kim, Myeong-Jin
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2012, 199 (04) : 809 - 815
  • [7] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [8] Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
    Folprecht, Gunnar
    Gruenberger, Thomas
    Bechstein, Wolf O.
    Raab, Hans-Rudolf
    Lordick, Florian
    Hartmann, Joerg T.
    Lang, Hauke
    Frilling, Andrea
    Stoehlmacher, Jan
    Weitz, Juergen
    Konopke, Ralf
    Stroszczynski, Christian
    Liersch, Torsten
    Ockert, Detlev
    Herrmann, Thomas
    Goekkurt, Eray
    Parisi, Fabio
    Koehne, Claus-Henning
    [J]. LANCET ONCOLOGY, 2010, 11 (01) : 38 - 47
  • [9] Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer - Analysis of 1001 consecutive cases
    Fong, Y
    Fortner, J
    Sun, RL
    Brennan, MF
    Blumgart, LH
    [J]. ANNALS OF SURGERY, 1999, 230 (03) : 309 - 318
  • [10] Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents
    Garcia-Alfonso, Pilar
    Ferrer, Ana
    Gil, Silvia
    Duenas, Rosario
    Teresa Perez, Maria
    Molina, Raquel
    Capdevila, Jaume
    Jose Safont, Maria
    Castanon, Carmen
    Maria Cano, Juana
    Lara, Ricardo
    [J]. TARGETED ONCOLOGY, 2015, 10 (04) : 453 - 465